Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma
Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC).A total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2–10 times. Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy.HCC recurrence rates at the end of first and second year were 18.1 and 22.1% in patients with once of HCC therapy, 28.2 and 41.6% in those with 2–3 times of therapy, and 60.2 and 74.5% in those with 4 or more times of therapy, respectively (P < 0.0001). Recurrence rates were compared between 89 patients with DAA therapy after initial HCC therapy and 89 age-, gender-, and BCLC staging-matched patients without antiviral therapy after initial HCC therapy. HCC recurrence rates at first and second year were 18.1 and 25.0% in patients with DAA therapy and 21.8 and 46.5% in those without DAA therapy, respectively (P = 0.003). Multivariate analysis showed DAA therapy significantly decreased recurrence rate with a hazard ratio of 0.353 (confidence interval: 0.191–0.651) after adjustment with covariates of tumor multiplicity, alpha-fetoprotein value, and prothrombin time.DAA therapy significantly decreased recurrence rate when it was performed after initial HCC therapy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 62(2017), 10, Seite 2932-2942 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ikeda, Kenji [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1007/s10620-017-4739-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1996880071 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1996880071 | ||
| 003 | DE-627 | ||
| 005 | 20230715071419.0 | ||
| 007 | tu | ||
| 008 | 171125s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-017-4739-z |2 doi | |
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1996880071 | ||
| 035 | |a (DE-599)GBVOLC1996880071 | ||
| 035 | |a (PRQ)p1021-9bf252b2e02f73204debe3111fda16dea9ce413616e28851986380f4d19649670 | ||
| 035 | |a (KEY)0016777020170000062001002932directactingantiviralsdecreasedtumorrecurrenceafte | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 100 | 1 | |a Ikeda, Kenji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC).A total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2–10 times. Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy.HCC recurrence rates at the end of first and second year were 18.1 and 22.1% in patients with once of HCC therapy, 28.2 and 41.6% in those with 2–3 times of therapy, and 60.2 and 74.5% in those with 4 or more times of therapy, respectively (P < 0.0001). Recurrence rates were compared between 89 patients with DAA therapy after initial HCC therapy and 89 age-, gender-, and BCLC staging-matched patients without antiviral therapy after initial HCC therapy. HCC recurrence rates at first and second year were 18.1 and 25.0% in patients with DAA therapy and 21.8 and 46.5% in those without DAA therapy, respectively (P = 0.003). Multivariate analysis showed DAA therapy significantly decreased recurrence rate with a hazard ratio of 0.353 (confidence interval: 0.191–0.651) after adjustment with covariates of tumor multiplicity, alpha-fetoprotein value, and prothrombin time.DAA therapy significantly decreased recurrence rate when it was performed after initial HCC therapy. | ||
| 540 | |a Nutzungsrecht: © Springer Science+Business Media, LLC 2017 | ||
| 650 | 4 | |a Biochemistry, general | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a Sustained virological response (SVR) | |
| 650 | 4 | |a Hepatology | |
| 650 | 4 | |a Direct-acting antivirals (DAA) | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Transplant Surgery | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Hepatocellular carcinoma (HCC) | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a Gastroenterology | |
| 650 | 4 | |a Liver cancer | |
| 700 | 1 | |a Kawamura, Yusuke |4 oth | |
| 700 | 1 | |a Kobayashi, Masahiro |4 oth | |
| 700 | 1 | |a Kominami, Yoko |4 oth | |
| 700 | 1 | |a Fujiyama, Shunichiro |4 oth | |
| 700 | 1 | |a Sezaki, Hitomi |4 oth | |
| 700 | 1 | |a Hosaka, Tetsuya |4 oth | |
| 700 | 1 | |a Akuta, Norio |4 oth | |
| 700 | 1 | |a Saitoh, Satoshi |4 oth | |
| 700 | 1 | |a Suzuki, Fumitaka |4 oth | |
| 700 | 1 | |a Suzuki, Yoshiyuki |4 oth | |
| 700 | 1 | |a Arase, Yasuji |4 oth | |
| 700 | 1 | |a Kumada, Hiromitsu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d New York, NY. : Springer., 1979 |g 62(2017), 10, Seite 2932-2942 |w (DE-627)129894036 |w (DE-600)304250-9 |w (DE-576)015213218 |x 0163-2116 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2017 |g number:10 |g pages:2932-2942 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1007/s10620-017-4739-z |3 Volltext |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1942511779 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2017 |e 10 |h 2932-2942 | ||